WO2025101049A1 - Lipolytic injection composition - Google Patents

Abstract

The present invention relates to a lipolytic injection composition having a superior effect of reducing pain during treatment, as well as improving solubility and maintaining stability of deoxycholic acid (DCA), by comprising deoxycholic acid and cyclodextrins at the optimal composition ratio and adjusting the pH to the range of 7.0 to 7.7.

Description

Fat-dissolving injection composition

The present invention relates to a fat-dissolving injection composition with improved stability and pain relief during treatment.

Injection lipolysis is a cosmetic procedure in which a mixture of drugs is injected into the patient with the aim of destroying fat cells, usually based on phosphatidylcholine (PPC) and deoxycholate (DCA). The treatment area can range from the abdomen, thighs and buttocks to the neck and the back of the arms.

Deoxycholic acid (DCA) is openly used in combination with phosphatidylcholine (PPC) in fat-dissolving injections. Deoxycholic acid (DCA) physically destroys cell membranes and induces fat cell destruction, causing necrosis, inflammation, and fat removal. It is particularly effective in reducing submental fat, and is widely used.

Meanwhile, deoxycholic acid (DCA) has a problem that it precipitates over time, which affects bioavailability and stability, and causes pain during injection. In this regard, patent document 1 uses amino acids, but the problem of causing pain still exists because the pH is relatively high at 7.0 to 8.5 or higher, and there is also a problem that it goes beyond the range required by the industry in terms of solubility and stability.

Therefore, there is an urgent need to develop a fat-dissolving injection that can improve solubility, stability, and pain during injection.

The purpose of the present invention is to solve the problems described above, and to provide a fat-dissolving injection composition that is excellent in reducing pain during treatment while achieving improved solubility and maintaining stability of deoxycholic acid (DCA).

To achieve the above purpose, a fat-dissolving injection composition according to one embodiment of the present invention contains 100 parts by weight of deoxycholic acid and 500 to 1000 parts by weight of cyclodextrin, and satisfies a pH range of 7.0 to 7.7.

In addition, the composition may further comprise lidocaine base, hydrochloride or a mixture thereof, in an amount of 10 to 100 parts by weight based on 100 parts by weight of the deoxycholic acid.

Additionally, the composition may include one or more selected from disodium phosphate, sodium hydroxide and sodium chloride.

In addition, the composition may contain 10 to 20 parts by weight of disodium phosphate, 10 to 20 parts by weight of sodium hydroxide, and 15 to 35 parts by weight of sodium chloride based on 100 parts by weight of the deoxycholic acid.

Additionally, the composition may not cause precipitation under temperature conditions of 60°C or less.

According to one embodiment of the present invention, a fat-dissolving injection composition can be excellent in reducing pain during treatment while achieving improved solubility and maintaining stability of deoxycholic acid by configuring deoxycholic acid (DCA) and cyclodextrin in an optimal composition ratio and adjusting the pH to a range of 7.0 to 7.7.

Figure 1 is a photograph showing a finished product of a fat-dissolving injection composition according to one embodiment of the present invention.

Figures 2 and 3 are diagrams and photographs showing the results according to Experimental Example 3.

Hereinafter, the present invention will be described in detail with reference to the attached drawings as implementation examples of the present invention. However, the following implementation examples are presented as examples of the present invention, and if it is judged that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description thereof may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the following claims and equivalents interpreted therefrom.

In addition, the terms used in this specification are terms used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator, or the customs of the field to which the present invention belongs. Therefore, the definitions of these terms should be made based on the contents throughout this specification. Throughout the specification, when a part is said to “include” a certain component, this does not mean that other components are excluded, but rather that other components can be included, unless specifically stated otherwise.

Throughout this specification, '%' used to indicate the concentration of a particular substance, unless otherwise stated, is %(w/w) for solid/solid, %(w/v) for solid/liquid, and %(v/v) for liquid/liquid.

Hereinafter, a fat-dissolving injection composition according to one embodiment of the present invention will be described in detail.

The fat-dissolving injection composition of the present embodiment contains deoxycholic acid (DCA) and cyclodextrin, and satisfies a pH range of 7.0 to 7.7, thereby improving the solubility and maintaining stability of deoxycholic acid and reducing pain during treatment. For example, the fat-dissolving injection composition of the present embodiment is provided in a form as shown in Fig. 1, and satisfies a pH condition of 7.0 to 7.7 while containing lidocaine base, lidocaine hydrochloride, or a mixture thereof, so that precipitation may not occur, and for example, since precipitation does not occur for 31 days or more under a temperature condition of 60°C or lower and for 90 days or more under a temperature condition of 40°C or lower, it may be very excellent in terms of maintaining stability.

Deoxycholic acid (DCA) is one of the secondary bile salts, which are metabolic byproducts of intestinal bacteria, and is a substance used for non-surgical removal of localized fat deposits. Deoxycholic acid (DCA) physically destroys cell membranes, inducing the destruction of fat cells, causing necrosis, inflammation, and fat removal, and may be particularly effective in reducing submental fat. However, deoxycholic acid (DCA) has a problem that it precipitates over time, affecting its bioavailability and stability. Therefore, in this example, it was used together with cyclodextrins, which will be described below, to solve the above-mentioned problem.

Cyclodextrins are substances used to increase the solubility of deoxycholic acid (DCA) and prevent precipitation. There are three types: alpha, beta, and gamma, which can be distinguished by their glucopyranose units. In particular, beta is composed of seven D-glucopyranose units and forms a complex with a guest molecule, and this complex formation can be a factor that improves solubility, bioavailability, and stability. Such cyclodextrins can be included in an amount of 500 to 1,000 parts by weight based on 100 parts by weight of deoxycholic acid. If the cyclodextrin is less than 500 parts by weight, it cannot increase the solubility of deoxycholic acid, so precipitation can easily occur, and if it exceeds 1,000 parts by weight, it can cause hemolysis, which is not preferable.

It is desirable to maintain the pH range of the composition at 7.0 to 7.7, because if the pH is lower than 7.0, side effects such as inflammation may occur, and pain may occur when the composition is injected into the patient's body, and DCA may precipitate, and if the pH exceeds 7.7, the stability of lidocaine decreases, which is undesirable. Therefore, it is important to maintain the appropriate pH range of the composition in order to minimize side effects and improve stability.

In this embodiment, lidocaine, a type of local anesthetic, may be included for the purpose of reducing pain when used as an injection. Lidocaine has the characteristics of increasing cell membrane permeability and facilitating penetration into the site of action due to the increase in non-ionized forms in the base, thereby enhancing fat solubility and causing nerve blockade immediately upon injection, thereby significantly reducing injection pain. For example, lidocaine may include lidocaine base, lidocaine hydrochloride (Lidocaine HCl), or a mixture thereof. Such lidocaine may be included in an amount of 10 to 100 parts by weight based on 100 parts by weight of deoxycholic acid. If the amount of lidocaine is less than 10 parts by weight, the pain-reducing effect may be minimal, and if it exceeds 100 parts by weight, side effects such as neuropathy, decreased myocardial contractility, and decreased blood pressure may occur. The above-described content of lidocaine may be an appropriate range that is therapeutically effective while not being harmful to the patient, and provides advantages in terms of convenience of the procedure and patient compliance with medication.

It may contain at least one selected from disodium phosphate, sodium hydroxide and sodium chloride, and for example, it may contain 10 to 20 parts by weight of disodium phosphate, 10 to 20 parts by weight of sodium hydroxide and 15 to 35 parts by weight of sodium chloride based on 100 parts by weight of deoxycholic acid. The contents of the above-mentioned disodium phosphate, sodium hydroxide and sodium chloride may be in a range that can provide therapeutically effective properties while increasing patient compliance.

In this embodiment, the fat-dissolving injection composition may include water and a pH regulator. The pH regulator may be at least one selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, triethylamine, diethanolamine, sodium phosphate, disodium biphosphate, arginine, lysine, histidine, ascorbic acid, lactic acid, malic acid, fumaric acid, citric acid, tartaric acid, succinic acid, hydrochloric acid, phosphoric acid, and acetic acid, for example, sodium hydroxide and hydrochloric acid. The pH regulator may be a mixture of a basic pH regulator and an acidic pH regulator, and the content thereof may be adjusted as needed. The pH regulator may be prepared and applied in the form of an aqueous solution or solution so that pH control is easy. In this embodiment, the form and content of the pH regulator are not significantly limited.

The fat-dissolving injection composition of the present invention can be directly injected into the subcutaneous fat layer of the patient's body where fat is accumulated, thereby selectively destroying fat cells, thereby causing a reduction in fat volume. Here, the body where the patient's fat is accumulated can be at least one area selected from under the eyes, under the chin, arms, buttocks, calves, thighs, back, armpits, ankles, and stomach.

Hereinafter, the present invention will be described in more detail using examples. It will be apparent to those skilled in the art that these examples are only intended to explain the present invention more specifically and that the scope of the present invention is not limited by these examples.

Examples 1 to 9. Preparation of fat-dissolving injection

Disodium phosphate (1.42 mg/mL), sodium hydroxide (1.43 mg/mL), and sodium chloride (18 mL) were added to purified water and stirred at 750 rpm for 20 minutes. Cyclodextrin was then added in the amount listed in Table 1 and stirred further. Then, 10 mg/mL of deoxycholic acid (DCA) was added and stirred for 30 minutes to sufficiently dissolve. The pH of the solution was adjusted using hydrochloric acid and sodium hydroxide. The final volume was adjusted to 20 mL with purified water, filled into vials, and stored.

division
(mg/mL) Example 1 2 3 4 5 6 7 8 9 Benzyl alcohol - - - - - - - - - β-cyclodextrin 100 100 100 75 75 75 50 50 50 γ-cyclodextrin - - - - - - - - - Sodium chloride 1.84 1.84 1.84 2.38 2.38 2.38 3.05 3.05 3.05 pH 7.7 7.4 7.0 7.7 7.4 7.0 7.7 7.4 7.0

Examples 10 to 21. Preparation of fat-dissolving injection

Disodium phosphate (1.42 mg/mL), sodium hydroxide (1.43 mg/mL), and sodium chloride (18 mL) were added to purified water and stirred at 750 rpm for 20 minutes. Cyclodextrin was then added in the amount listed in Table 2 and stirred further. Then, 10 mg/mL of deoxycholic acid was added and stirred for 30 minutes to sufficiently dissolve, and then 3 mg/mL of lidocaine hydrochloride was added and stirred. The pH of the solution was adjusted using hydrochloric acid and sodium hydroxide. After adjusting the final volume to 20 mL with purified water, it was filtered through a syringe filter, filled into vials, and stored.

For Examples 16 to 21, the final volume was adjusted to 20 mL, and the vials were filled and stored.

division
(mg/mL) Example 10 11 12 13 14 15 Benzyl alcohol - - - - - - β-cyclodextrin 100 60 50 40 - - γ-cyclodextrin - - - - 100 50 Sodium chloride 1.84 2.78 3.05 3.31 1.84 3.05 pH 7.7 7.7 7.7 7.7 7.7 7.7 division
(mg/mL) Example 16 17 18 19 20 21 Benzyl alcohol - - - - - - β-cyclodextrin 100 100 75 75 50 50 γ-cyclodextrin - - - - - - Sodium chloride 1.84 1.84 2.38 2.38 3.05 3.05 pH 7.4 7.0 7.4 7.0 7.4 7.0

Examples 22 to 27. Preparation of fat-dissolving injection

It was manufactured in the same manner as Examples 10 to 21, except that lidocaine base was used instead of lidocaine hydrochloride.

division
(mg/mL) Example 22 23 24 25 26 27 Benzyl alcohol - - - - - - β-cyclodextrin 100 100 75 75 50 50 γ-cyclodextrin - - - - - - Sodium chloride 1.84 1.84 2.38 2.38 3.05 3.05 pH 7.7 7.4 7.7 7.4 7.7 7.4

Comparative examples 1 to 6. Preparation of fat-dissolving injection

Disodium phosphate (1.42 mg/mL), sodium hydroxide (1.43 mg/mL), and sodium chloride (4.38 mg/mL) were added to 18 mL of purified water and stirred at 750 rpm for 20 minutes. 9 mg/mL benzyl alcohol was then added and stirred further. Then, 10 mg/mL deoxycholic acid was added and stirred for 30 minutes to sufficiently dissolve, and then lidocaine base or hydrochloride was added and stirred. The pH of the solution was adjusted using hydrochloric acid and sodium hydroxide, and the final volume was adjusted to 20 mL with purified water, filled into vials, and stored.

division Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Benzyl alcohol 9 9 9 9 9 9 Lidocaine base - - 3 3 - - Lidocaine hydrochloride - - - - 3 3 Sodium chloride 4.38 4.38 4.38 4.38 4.38 4.38 pH 7.7 8.3 7.7 8.3 7.7 8.3

Experimental Example 1. Evaluation of DCA content

In order to confirm the change in content according to the storage temperature conditions of Example 20, the content was measured after storage at room temperature, 40°C, and 60°C, and the results are shown in Table 5.

Storage temperature conditions Content (%) DCA content (%) during manufacturing Room temperature 99.7 100.0 40 ^o C 101.6 100.0 60 ^o C 99.1 100.0

Referring to Table 5, the content of DCA was confirmed to be almost the same as at the time of manufacture, indicating that the DCA component was stable and not decomposed when containing 5% beta-cyclodextrin (Example 20).

Experimental Example 2. Stability Evaluation

In order to confirm the stability of the fat-dissolving injection formulation according to the examples and comparative examples, the following experiments were conducted.

Experimental Example 2-1. Evaluation of the stability of lipolytic injections according to the presence or absence of lidocaine

Comparative Examples 1 to 6 were stored at room temperature and 60°C for 1 day, 1 week, and 1 month, respectively, and the presence or absence of precipitation was compared, and the results are shown in Table 6.

Storage conditions division 1 day 1 week 1 month Room temperature Comparative Example 1 Ⅹ Ⅹ Ⅹ Comparative Example 2 Ⅹ Ⅹ Ⅹ Comparative Example 3 Sedimentation Sedimentation Sedimentation Comparative Example 4 Ⅹ Ⅹ Ⅹ Comparative Example 5 Sedimentation Sedimentation Sedimentation Comparative Example 6 Sedimentation Sedimentation Sedimentation 60℃ Comparative Example 1 Ⅹ Sedimentation Sedimentation Comparative Example 2 Ⅹ Ⅹ Ⅹ Comparative Example 3 Sedimentation Sedimentation Sedimentation Comparative Example 4 Ⅹ Ⅹ Sedimentation Comparative Example 5 Sedimentation Sedimentation Sedimentation Comparative Example 6 Sedimentation Sedimentation Sedimentation

Referring to Table 6, it was confirmed that precipitation generally occurred when the pH was 8.3 or lower under temperature conditions of room temperature and 60℃, and that precipitation occurred within 1 day when lidocaine was added.

Experimental Example 2-2. Stability Evaluation of Fat-Dissolving Injection with or without Cyclodextrin Addition

Examples 1 to 9 and Comparative Example 1 were stored at room temperature, 40°C, and 60°C for 1 day, 1 week, and 1 month, respectively, and the presence or absence of precipitation was compared, and the results are shown in Table 7.

Storage conditions division 1 day 1 week 1 month Room temperature Example 1 Ⅹ Ⅹ Ⅹ Example 2 Ⅹ Ⅹ Ⅹ Example 3 Ⅹ Ⅹ Ⅹ Example 4 Ⅹ Ⅹ Ⅹ Example 5 Ⅹ Ⅹ Ⅹ Example 6 Ⅹ Ⅹ Ⅹ Example 7 Ⅹ Ⅹ Ⅹ Example 8 Ⅹ Ⅹ Ⅹ Example 9 Ⅹ Ⅹ Ⅹ Comparative Example 1 Ⅹ Ⅹ Ⅹ 40℃ Example 1 Ⅹ Ⅹ Ⅹ Example 2 Ⅹ Ⅹ Ⅹ Example 3 Ⅹ Ⅹ Ⅹ Example 4 Ⅹ Ⅹ Ⅹ Example 5 Ⅹ Ⅹ Ⅹ Example 6 Ⅹ Ⅹ Ⅹ Example 7 Ⅹ Ⅹ Ⅹ Example 8 Ⅹ Ⅹ Ⅹ Example 9 Ⅹ Ⅹ Ⅹ Comparative Example 1 Ⅹ Ⅹ Ⅹ 60℃ Example 1 Ⅹ Ⅹ Ⅹ Example 2 Ⅹ Ⅹ Ⅹ Example 3 Ⅹ Ⅹ Ⅹ Example 4 Ⅹ Ⅹ Ⅹ Example 5 Ⅹ Ⅹ Ⅹ Example 6 Ⅹ Ⅹ Ⅹ Example 7 Ⅹ Ⅹ Ⅹ Example 8 Ⅹ Ⅹ Ⅹ Example 9 Ⅹ Ⅹ Ⅹ Comparative Example 1 Ⅹ Sedimentation Sedimentation

Referring to Table 7, it was confirmed that Examples 1 to 9 with added cyclodextrin had the same stability as Comparative Example 1 at room temperature and 40°C, but at 60°C, Examples 1 to 9 increased the stability for DCA solutions for up to 1 month, while Comparative Example 1 precipitated within 1 week.

Experimental Example 2-3. Stability Evaluation of Fat-Dissolving Injection According to the Addition or Absence of Litocine Hydrochloride and Cyclodextrin

Examples 10 to 21 and Comparative Example 3 were stored at room temperature, 40°C, and 60°C for 1 day, 1 week, and 1 month, respectively, and the presence or absence of precipitation was compared, and the results are shown in Table 8.

Storage conditions division 1 day 1 week 1 month Room temperature Example 10 Ⅹ Ⅹ Ⅹ Example 11 Ⅹ Ⅹ Ⅹ Example 12 Ⅹ Ⅹ Ⅹ Example 13 Ⅹ Ⅹ Sedimentation Example 14 Ⅹ Ⅹ Ⅹ Example 15 Ⅹ Ⅹ Ⅹ Example 16 Ⅹ Ⅹ Ⅹ Example 17 Ⅹ Ⅹ Ⅹ Example 18 Ⅹ Ⅹ Ⅹ Example 19 Ⅹ Ⅹ Ⅹ Example 20 Ⅹ Ⅹ Ⅹ Example 21 Ⅹ Ⅹ Ⅹ Comparative Example 3 Sedimentation Sedimentation Sedimentation 40℃ Example 10 Ⅹ Ⅹ Ⅹ Example 11 Ⅹ Ⅹ Ⅹ Example 12 Ⅹ Ⅹ Ⅹ Example 13 Ⅹ Ⅹ Sedimentation Example 14 Ⅹ Ⅹ Ⅹ Example 15 Ⅹ Ⅹ Ⅹ Example 16 Ⅹ Ⅹ Ⅹ Example 17 Ⅹ Ⅹ Ⅹ Example 18 Ⅹ Ⅹ Ⅹ Example 19 Ⅹ Ⅹ Ⅹ Example 20 Ⅹ Ⅹ Ⅹ Example 21 Ⅹ Ⅹ Ⅹ Comparative Example 3 Sedimentation Sedimentation Sedimentation 60℃ Example 10 Ⅹ Ⅹ Ⅹ Example 11 Ⅹ Ⅹ Ⅹ Example 12 Ⅹ Ⅹ Ⅹ Example 13 Sedimentation Sedimentation Sedimentation Example 14 Ⅹ Ⅹ Ⅹ Example 15 Ⅹ Ⅹ Ⅹ Example 16 Ⅹ Ⅹ Ⅹ Example 17 Ⅹ Ⅹ Ⅹ Example 18 Ⅹ Ⅹ Ⅹ Example 19 Ⅹ Ⅹ Ⅹ Example 20 Ⅹ Ⅹ Ⅹ Example 21 Ⅹ Ⅹ Ⅹ Comparative Example 3 Sedimentation Sedimentation Sedimentation

Referring to Table 8, in the case of Comparative Example 3 where only lidocaine hydrochloride was added, precipitation occurred within 24 hours, but in the cases of Examples 10 to 21 where lidocaine hydrochloride and cyclodextrin were added together, stability was higher than that of Comparative Example 3, and stability was confirmed as no precipitation occurred for one month.

In addition, for Examples 16 to 21, it was found that the stability was constant for up to one month at three different temperatures despite the increase in pH, and it was confirmed that the stability was maintained for one month.

Therefore, it was found that cyclodextrin increases the solubility and improves the stability of DCA solution.

Experimental Example 2-4. Stability Evaluation of Fat-Dissolving Injection According to the Addition or Absence of Litocine Base and Cyclodextrin

Examples 22 to 27 and Comparative Example 5 were stored at room temperature, 40°C, and 60°C for 1 day, 1 week, and 1 month, respectively, and the presence or absence of precipitation was compared, and the results are shown in Table 9.

Storage conditions division 1 day 1 week 1 month Room temperature Example 22 Ⅹ Ⅹ Ⅹ Example 23 Ⅹ Ⅹ Ⅹ Example 24 Ⅹ Ⅹ Ⅹ Example 25 Ⅹ Ⅹ Ⅹ Example 26 Ⅹ Ⅹ Ⅹ Example 27 Ⅹ Ⅹ Ⅹ Comparative Example 5 Ⅹ Sedimentation Sedimentation 40℃ Example 22 Ⅹ Ⅹ Ⅹ Example 23 Ⅹ Ⅹ Ⅹ Example 24 Ⅹ Ⅹ Ⅹ Example 25 Ⅹ Ⅹ Ⅹ Example 26 Ⅹ Ⅹ Ⅹ Example 27 Ⅹ Ⅹ Ⅹ Comparative Example 5 Sedimentation Sedimentation Sedimentation 60℃ Example 22 Ⅹ Ⅹ Ⅹ Example 23 Ⅹ Ⅹ Ⅹ Example 24 Ⅹ Ⅹ Ⅹ Example 25 Ⅹ Ⅹ Ⅹ Example 26 Ⅹ Ⅹ Ⅹ Example 27 Ⅹ Ⅹ Ⅹ Comparative Example 5 Sedimentation Sedimentation Sedimentation

Referring to Table 9, in the case of Comparative Example 5, where only lidocaine base was added, precipitation occurred within 24 hours, but in the case of Examples 22 to 27, where lidocaine base and cyclodextrin were added together, it was confirmed that stability was observed overall, similar to Experimental Examples 2-3.

Therefore, it was confirmed that cyclodextrin inhibits the precipitation of DCA.

Experimental Example 3. In vitro anti-obesity efficacy test evaluation

To confirm the in vitro anti-obesity effect of a fat-dissolving injection according to the example, the following experiment was conducted.

3T3-L1 preadipocytes were allowed to reach the confluent stage, and were treated with Example 1 and Example 10 at concentrations of 25, 50, and 75 μg/mL, respectively, and cultured in MDI media for 3 days, Insulin media for 2 days, and Induction media for 2 days. Then, all media were removed and replaced with PBS, and the cells were fixed in 10% formaldehyde for 30 minutes and washed with PBS. After staining with Oil Red O for 1 hour, they were observed using a microscope. For quantitative analysis, 100% isopropanol was used, and the cells were placed in a 96-well plate and the absorbance was measured at 500 nm. The results are shown in Figs. 2 and 3.

Referring to Figure 2, in the no treatment group and the negative control group (normal saline), the degree of intracellular fat accumulation was not reduced, but in the Example 1 treatment group, the degree of intracellular fat accumulation was significantly reduced. In particular, in the Example 10 medium-concentration (50 μg/mL) and high-concentration (75 μg/mL) treatment groups, the degree of intracellular fat accumulation was further reduced compared to the negative control group at the same DCA concentration (**: P<0.01, #: P<0.05, ##: P<0.01, n=3).

Although exemplary embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims also fall within the scope of the present invention.

All technical terms used in the present invention, unless otherwise defined, are used with the same meaning as commonly understood by those skilled in the art in the relevant field of the present invention. The contents of all publications cited as references in this specification are incorporated into the present invention.

Claims (6)

100 parts by weight of deoxycholic acid; and Containing 500 to 1000 parts by weight of cyclodextrin; A fat-dissolving injection composition having a pH range of 7.0 to 7.7. In the first paragraph, The composition further comprises lidocaine base, lidocaine hydrochloride or a mixture thereof, wherein the composition comprises 10 to 100 parts by weight of a fat-dissolving injection based on 100 parts by weight of the deoxycholic acid. In the first paragraph, The composition is a fat-dissolving injection composition further comprising at least one selected from disodium phosphate, sodium hydroxide and sodium chloride. In the first paragraph, The composition is a fat-dissolving injection composition containing 10 to 20 parts by weight of disodium phosphate, 10 to 20 parts by weight of sodium hydroxide, and 15 to 35 parts by weight of sodium chloride based on 100 parts by weight of the deoxycholic acid. In the first paragraph, The composition comprises a pH adjusting agent, wherein the pH adjusting agent comprises at least one selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, triethylamine, diethanolamine, sodium phosphate, disodium biphosphate, arginine, lysine, histidine, ascorbic acid, lactic acid, malic acid, fumaric acid, citric acid, tartaric acid, succinic acid, hydrochloric acid, phosphoric acid, and acetic acid. In the first paragraph, The composition above is a fat-dissolving injection composition that does not cause precipitation under temperature conditions of 60°C or less.

Images